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Abstract
Glutamate receptors of the N-methyl-D-aspartate (NMDA) family are coincident detectors of pre- and postsynaptic
activity, allowing Ca2+ influx into neurons. These properties are central to neurological disease mechanisms and are
proposed to be the basis of associative learning and memory. In addition to the well-characterised canonical GluN2A
NMDAR isoform, large-scale open reading frames in human tissues had suggested the expression of a primate-specific
short GluN2A isoform referred to as GluN2A-S. Here, we confirm the expression of both GluN2A transcripts in human and
primate but not rodent brain tissue, and show that they are translated to two corresponding GluN2A proteins present in
human brain. Furthermore, we demonstrate that recombinant GluN2A-S co-assembles with the obligatory NMDAR
subunit GluN1 to form functional NMDA receptors. These findings suggest a more complex NMDAR repertoire in human
brain than previously thought.
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Introduction
NMDA receptors are activated by coincident glutamate
binding and intracellular depolarisation. Ca2+ entry via
NMDARs can gate long-term biochemical and gene ex-
pression changes that alter synaptic strength, which are
proposed as central to mechanisms of memory storage
[17] and neurodegenerative processes [9]. Our current
knowledge of NMDAR function is largely derived from
the study of rodent receptors and heterologous expression
of cloned rodent genes. Tetrameric NMDARs comprise
two obligatory GluN1 subunits and two GluN2 or GluN3
subunits, and in the adult forebrain GluN1/GluN2A,
GluN1/GluN2B diheteromers, and GluN1/GluN2A/
GluN2B triheteromers are the most common [18, 19].
The subunit combination confers the distinct biophysical
and pharmacological properties to the receptor channel.
The developmentally and anatomically regulated gene ex-
pression of NMDAR subunits, together with diverse post-
translational modification mechanisms and protein inter-
actions, determines the assembly, trafficking, synaptic or
extrasynaptic localisation and internalisation of NMDARs
(Reviewed in [16]) and their correct functioning is neces-
sary for human brain functions [5, 6, 21].
Homologous rodent and human NMDARs do share
highly conserved subunit sequences and exhibit almost
identical pharmacological properties [10]. However, large
scale open reading frame studies performed with mRNA
from a mix of human tissues [20, 28] have suggested that
in addition to the conserved NMDAR canonical isoform
of GluN2A in chordates, a shorter isoform is produced in
humans (GluN2A-S) generated by alternative splicing of
human GRIN2A (Fig. 1a). Here, we show that this alterna-
tive NMDAR isoform is expressed in the human and pri-
mate brain, and that it forms functional receptors together
with the obligatory subunit GluN1 [15]. The presence of
alternative NMDAR subunits not expressed in rodent
model systems indicates the existence of unexplored
neural mechanisms in human synapses with relevance to
normal function, ageing and neurological disease.
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Fig. 1 (See legend on next page.)
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Results and discussion
To test whether the GluN2A-S mRNA (GRIN2A) is
expressed in human brain, we designed primers (Fw1/
Rv1) flanking the region of exon 13 containing the 343
base pairs (bp) present only in GRIN2A (Fig. 1a). We
predicted two distinct amplicons (474 bp and 131 bp)
that would distinguish the GRIN2A and GRIN2A-S tran-
scripts, respectively (Fig. 1a). Following PCR using
cDNA from human brain (Table 1) as template, we ob-
served the presence of a ~ 131 bp amplicon. In contrast,
in mouse we observed one product of 474 bp, corre-
sponding to the canonical isoform, using Fw1/Rv1
primers and a pair of primers modified to exactly match
mouse Grin2A at the same location (mFw1/mRv1, Fig.
1b). If both short and long GRIN2A cDNAs are present in
the human sample, the synthesis of shorter cDNA could
overwhelm the early PCR cycles [27] and only generate the
short amplicon. Using an additional GRIN2A specific re-
verse primer (Rv2), we confirmed the presence of canonical
GRIN2A in this human cDNA sample (Fig. 1c). We ob-
served the 131 bp band in further adult brain cDNAs tested
with Fw1/Rv1 primer pair (Fig. 1d, two further samples not
shown). Although its expression levels increase develop-
mentally, GluN2A is expressed throughout the life course
[2]. We tested foetal human brain cDNA and confirmed
the expression of both GRIN2A and GRIN2A-S (Fig. 1e).
Table 1 Details of resected human brain tissue samples
Case Number Sex Age Reason for Surgery
004 M 52 Hippocampal sclerosis
007 F 21 DNET
008 M 71 Glioblastoma
010 M 28 Hippocampal sclerosis
011 F 42 Glioma
014 M 32 Hippocampal sclerosis
016 F 36 Hippocampal sclerosis
017 F 62 Hippocampal sclerosis
018 M 30 Cavernous malformation
019 M 19 Arteriovenous malformation
020 F 70 Arteriovenous malformation
021 M 49 Hippocampal sclerosis
022 F 58 Subarachnoid haemorrhage
024 F 50 Cavernous malformation
026 M 27 Mesial temporal DNET with signal changes in the hippocampus
028 F 38 Epilepsy
030 M 40 Cortical dysplasia
032 F 29 Tumour resection
037 M 52 Glioma
039 F 58 Tumour resection
041 M 41 Hippocampal sclerosis
M Male, F Female, DNET Dysembryoplastic neuroepithelial tumour
(See figure on previous page.)
Fig. 1 The GRIN2A gene has two transcript variants in human and primate but not mouse brain. a A short isoform of GRIN2A transcript was
predicted by open reading frame studies. The published sequence of GRIN2A-S suggests that the final exon (exon 13) is missing two nucleotide
regions compared to the canonical transcript: firstly, the lack of 343 nucleotides generates a putative exon 14 in GRIN2A-S (splice site shown in Ai)
and the final 206 nucleotides of the canonical form are lost altogether. We designed primers to amplify the region of variance between the two
isoforms (Fig. 1, Fw1/Rv1) generating an amplicon of 474 bp in GRIN2A and 131 bp in GRIN2A-S. A second reverse primer was designed to amplify
canonical GRIN2A selectively (Fig. 1a, Rv2) generating an amplicon of 380 bp. b-f RT-PCR amplification end products. Control conditions indicate
no cDNA template was used in PCR b In human cDNA, only the short form of GRIN2A was observed likely due to preferential amplification in
PCR, whereas only a long product of 474 bp was seen in mouse using either human or mouse specific primers. c The Fw1/Rv2 primer pair was
used to confirm expression of canonical GRIN2A in the same human sample as shown in (B). d 3 other human cortical samples with GRIN2A-S
amplified. e Both the short and long amplicons were observed in human foetal cDNA. f GRIN2A-S was observed in primate (Rhesus) brain cDNA.
g Sequencing of human and primate RT-PCR short amplicons confirmed the presence of the putative splice site shown in Ai
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Thus, our data confirm the presence of both canonical
GRIN2A and the novel GRIN2A-S transcripts in human
brain tissue samples.
A BLAST search of the 131 bp sequence amplified by
primers Fw1/Rv1 provided primate-specific predictive
hits. To confirm whether GRIN2A-S transcript is present
in primate brain, we tested Rhesus macaque brain cDNA
with Fw1/Rv1 primers and confirmed the presence of
GRIN2A-S (Fig. 1f ). We sequenced the shorter PCR
products for both the adult human and primate samples
and confirmed the presence of the exact splice site re-
ported in the European Nucleotide Archive (Coding:
AAI17132.1; [20] (Fig. 1a,g).
Furthermore, we aimed to evaluate whether the
GRIN2A and GRIN2A-S transcripts were translated into
the corresponding proteins. To this end, we hypothe-
sised that if both transcripts are translated into proteins,
two protein bands corresponding to GluN2A and
Fig. 2 Two GluN2A protein bands are observed in human but not mouse brain. a Topology of the GluN2A subunit of the NMDA receptor and of
GluN2A-S predicted from human mRNA studies. A spliced region is retained in canonical GluN2A leading to an alteration of the reading frame to
generate a diverging C-terminal sequence (red) with early truncation. Epitopes for the antibodies used are shown in green and are numbered. b
Immunoblots with specific antibodies against the canonical GluN2A and putative GluN2A-S protein in human and mouse cortical lysates. c
GluN2A proteins were pulled down with an N-terminal antibody. Band 2 was cut from Coomassie-stained polyacrylamide gel and analysed by
mass spectrometry. IP, immunoprecipitate. FT, flowthrough d A set of 14 peptides were confirmed to be present in this band. Figure shows
tryptic peptides from band 2 coverage to either canonical GluN2A amino acid sequence (Uniprot: Q12879) or GluN2AS (Q12879–2, predicted)
confirming band 2 contains GluN2A protein. e Homogenate from freshly frozen cortical human tissue probed with the GluN2A antibody Abcam
133,265 (select blots shown on top) and quantification of GluN2A-S / GluN2A immunoreactivity (bottom). See Table 1 for human tissue sample
details. f Recombinant GluN2A-S co-expressed with GluN1 in HEK293 cells produces functional NMDARs as demonstrated by a typical J-shaped
curve in response to 40mM NMDA in response to a slow ramp of voltage (− 70 to + 50mV, 3 s)
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GluN2A-S in human homogenate would be immunode-
tected by a GluN2A antibody targeting an epitope con-
served between the canonical and short GluN2A
isoforms (Fig. 2a,b). Importantly, Western blot analysis
from human brain homogenates confirmed the presence
of two immunoreactive bands with a molecular weight
corresponding to the predicted GluN2A and GluN2A-S
isoforms. On the contrary, a single immunoreactive
band with the high molecular weight (corresponding to
the canonical GluN2A) was detected in mouse brain ly-
sates (Fig. 2b). Furthermore, using an antibody specific-
ally detecting a carboxy terminal epitope (exclusively
present in the canonical GluN2A isoform), we detected
the presence of a single band, with a molecular weight
corresponding to the canonical GluN2A subunit (Fig. 2a,
b). To confirm the identity of the low molecular weight
band, we immunoprecipitated GluN2A from human tis-
sue homogenates with an antibody against the conserved
N-terminal domain and analysed the primate-specific
band (Band 2, Fig. 2c) by mass spectrometry. This un-
biased method allowed the identification of 14 unique
peptides located within GluN2A residues 81–1022, con-
firming that this low molecular band contains the prox-
imal part of GluN2A, and thus discarding the potential
cross-reactivity of anti-GluN2A N-terminal antibody
(Fig. 2d). To assess the relative levels of GluN2A-S vs.
total GluN2A, human cortical homogenates from fresh-
frozen tissue resected from individuals 27–61 years of
age were analysed by Western blot and the quantifica-
tion showed that GluN2A-S immunoreactivity accounts
for 34 ± 4% of canonical GluN2A protein in cortical hu-
man brain homogenate (Table 1) and this fraction re-
mains constant across age (Fig. 2ei).
Finally, to test whether GluN2A-S can be incorporated
into functional NMDARs, we co-transfected HEK293 cells
with plasmids expressing GluN2A-S and GluN1 subunits
[15]. A slow voltage ramp delivered during local perfusion
with 40 μM NMDA and 10 μM glycine elicited a typical J-
shaped curve (Fig. 2fi), and subtraction of responses with-
out agonist (leak subtraction) revealed a typical NMDA
current with reversal potential near 0mV (Fig. 2eii). This
confirms that GluN2A-S subunits are able to assemble
with GluN1 subunits and become inserted into the plasma
membrane to form a functional NMDAR that likely plays
a role in human neural function.
Here we describe for the first time the brain expres-
sion of an uncharacterised, primate-specific NMDAR
subunit. The splice site for GluN2A-S suggests that it
will contain a diverging 19 aa sequence in its extreme C-
terminal domain (Fig. 2a), in addition to lacking the dis-
tal carboxy terminal domain (183 amino acids) that con-
tains PKC/SFK phosphorylation sites, two PDZ binding
motifs that allow synaptic localisation [4, 12, 14], and a
dileucin clathrin adaptor motif involved in receptor
internalisation [13]. Following many lines of published
evidence, these differences suggest that the dynamic regu-
lation of GluN2A-S in response to stimuli could diverge
from GluN2A subunit-containing NMDARs. This could
impact the number of receptors present synaptically or
extrasynaptically, the insertion of new receptors into the
membrane, their lateral diffusion and clustering into
synapses and their active removal. The potential changes
in human synapses compared to mouse neurons void of
GluN2A-S could result in distinct mechanisms involved in
activity-dependent plasticity of synapses, which will highly
depend upon its triheteromeric partners [1, 8, 19].
Together, our data suggest that GluN2A-S is a primate-
specific NMDAR subunit and a substantial component of
functional NMDARs in the adult human brain. Many neur-
onal mechanisms discovered in mice have been success-
fully recapitulated in humans. However, mounting
evidence suggests that there are important differences be-
tween rodent and human neurons that result in distinct
signal integration properties [22, 23, 26] and proteomic
composition of synapses [3]. Species differences may ultim-
ately impact the way in which human neural circuits can
be computationally modelled [7], and the translation of
pre-clinical findings into approved therapies [24]. Further
analyses of GluN2A-S spatio-temporal gene expression and
synaptic/ extrasynaptic localisation will enhance our know-
ledge of their functional role and may uncover NMDAR
trafficking mechanisms present only in primates and diver-
ging sequences may uncover novel therapeutic targets.
Materials and methods
Human brain tissue samples
All samples consisted of cortical tissue resected for access
to deeper brain lesions such as sclerotic hippocampus in
epileptic patients (the pathological tissue for these lesions
was not used). Informed consent was obtained from all pa-
tients to use surgically-resected putatively non-pathological
tissue not required for diagnostic purposes (see ethical ap-
proval declaration). Briefly, resected tissue was obtained
from temporal cortex of patients undergoing surgery for
the removal of deeper structures. Tissue was collected in
ice cold artificial cerebrospinal fluid [26] then taken to the
laboratory, frozen and kept at − 80 °C. Transfer time was of
the order of 10–15min.
Mouse brain tissue
Mice were decapitated following isoflurane anaesthesia
(see ethical approval declaration). Brains were extracted
in ice-cold ACSF and sliced or snap-frozen. All brain tis-
sue samples were stored in the -80C freezer until lysed.
RNA extraction and cDNA synthesis
Total RNA was isolated from human and mouse tissue
using Trizol and then purified using the RNeasy Mini kit
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(QIAGEN) following the manufacturer’s instructions.
cDNA was synthesised immediately from 200 ng of total
RNA per reaction using the SuperScript IV reverse tran-
scriptase and cDNA synthesis kit (INVITROGEN) ac-
cording to the manufacturer’s instructions. The cDNA
obtained was stored at − 80 °C. Human foetal cDNA
was obtained from Takara (Normal brain tissue
cDNA, pooled from 59 spontaneously aborted male/
female Caucasian fetuses, ages: 20–33 weeks). Rhesus
macaque cDNA was obtained from Amsbio (Normal
brain tissue, Female, 4.5 years).
PCR conditions and primers
PCR was performed on 1μg of cDNA using primers and
REDTaq® Readymix™ PCR Reaction Mix (Sigma-Aldrich)
for 40 cycles. DNA was denatured at 95 degree C and
extended at 72 degree C for 45 s each cycle. Products
were separated on a 1.5% agarose gel.
The following primers were used: Fw1: ATTCAGGC-
CACTTCACCATGAG, Rv1: ATCTCCCAATAAC-
CAAGCGTTG, Rv2: CTTGCTGTCCTCCAGACCTTGG
mFw1: ACTCAGGCCACTTTACCATGAG, and mRv1:
ATCTCCCAATAACTAAGCGTTG.
Plasmids
pEYFP-NR1a was a gift from Stefano Vicini (Addgene
plasmid # 17928; [15]). GRIN2A-S plasmid from Broad
Institute, was acquired from Source Bioscience (Tran-
script NM_001134408.2).
Western blotting
Equal amounts of protein (28 μg) were separated in 7.5%
acrylamide gels by SDS-PAGE and transferred onto nitro-
cellulose membranes. Membranes were blocked in 5% (w/
v) non-fat milk for 1 h at room temperature and incubated
overnight at 4 C in 5% (w/v) bovine serum albumin (BSA)
containing 0.1% (v/v) Tween-20 and one of the following
primary antibodies: anti-NMDAR2A (ab133265; 1:1000;
Abcam); and GAPDH (D16H11; 1:1000; CST) actin.
Membranes were washed 3 times with Tris-buffered saline
(TBS) containing 0.1% Tween-20 (TBS-T) and probed
with fluorophore-conjugated goat anti-mouse/−rabbit sec-
ondary antibody (1:10000; LI-COR). Proteins were visua-
lised using the Odyssey infrared scanner (LI-COR) using
Image Studio Light Software.
GluN2A pulldown
GluN2A was pulled down from 1 mg of protein
homogenate (in RIPA buffer) using 2 μg of Alomone
antibody AGG-002 beads. Eluate was run in SDS
page and stained with Coomassie dye. The lighter
band corresponding to putative GluN2A-S was cut
and analysed by LC-MS/MS [11].
HEK293T cell recordings
HEK293T cells were cultured at 37 C with 5% CO2 in
Dulbecco’s Modified Eagle Medium with glucose, L-
glutamine and pyruvate, 10% FBS and 1% Pen-Strep and
seeded at low density onto poly-L-lysine coated glass
coverslips for electrophysiology. Adherent cells were
transfected using JetPEI reagent with NR1a and
GluN2A-S plasmids at a 1:1 ratio and recorded after 48
h. Borosilicate glass micropipettes were pulled to pro-
duce a resistance of 4–6 mOhm and filled with intracel-
lular recording solution containing in mM: Gluconic
acid 70, Caesium chloride 10, sodium chloride 5, BAPTA
10, HEPES 10, GTP 0.3 ATP 4 and pH balanced to 7.3
with caesium hydroxide. Cells were perfused with aCSF
throughout recording containing, in mM: sodium chlor-
ide 126, calcium dichloride 2, glucose 10, magnesium
sulfate 2, potassium chloride 3, NaH2PO4 1.25 and
NaHCO3 26.4, and glycine 10 μM and pH regulated by
continuous bubbling of 95% oxygen, 5% CO2. Record-
ings with or without addition of NMDA 40 μM were
made in whole-cell voltage clamp and Matlab software
and amplified using an Axopatch 200B as previously de-
scribed [28].
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